TYMS and non-small cell lung carcinoma: This preclinical work suggests a potential role for FLT-PET imaging of TS inhibition as a means of early detection of NSCLC sensitivity to pemetrexed which could be a useful tool in cancer management if translated to the clinic, though one exploratory clinical trial of pemetrexed therapy in non-small cell lung cancer[12] did not see a correlation between the pemetrexed-induced “flare” and eventual therapy success.